Drug profile · INN
lotilaner
XDEMVY
lotilaner (XDEMVY) is a ectoparasiticide. Associated with Tarsus Pharmaceuticals. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — lotilaner
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 8
- Programs
- 7
- Data quality
- 0.89
Quick answer
lotilaner (XDEMVY) is a ectoparasiticide. Associated with Tarsus Pharmaceuticals. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Ectoparasiticide
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related patents
-
US 12364685
Isoxazoline parasiticide formulations
granted -
US 12213964
Isoxazoline parasiticide formulations
granted -
US 12171750
Isoxazoline parasiticide formulations and methods for treating blepharitis
granted -
US 11752137
Ophthalmic compositions for treating ocular Demodex using lotilaner formulations
granted -
US 11690826
Methods for treating demodex blepharitis using lotilaner formulations
granted -
US 11690827
Methods for treating ocular Demodex using lotilaner formulations
granted -
US 11197847
Isoxazoline parasiticide formulations and methods for treating blepharitis
granted -
US 10835517
Methods for treating ocular demodex using isoxazoline parasiticide formulations
granted
Frequently asked questions
What is lotilaner?
lotilaner (XDEMVY) is a ectoparasiticide. Associated with Tarsus Pharmaceuticals. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for lotilaner?
XDEMVY is a marketed brand name for lotilaner. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lotilaner?
lotilaner has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.